🚨 PhD position available 🚨 👀 We are excited to announce a fully funded PhD position in our lab, focused on developing personalized induced pluripotent stem cell (iPSC)-based models to study inherited retinal diseases as part of the Lifelong VISION consortium!

💡 Light matters 💡 Despite major advances in generating retinal cells in vitro, these cells are typically cultured in the dark. But why would cells develop light-sensitive features if there is no light around?

Congratulations Owen and many thanks to Alex and Amanda.

Congratulations Owen on your PhD defence 🥳🎉🥂huge thank you to examiners @jandritu.bsky.social and @amandajcarr.bsky.social

🚨𝗙𝗶𝗻𝗮𝗹 𝗪𝗲𝗲𝗸 𝘁𝗼 𝗔𝗽𝗽𝗹𝘆 𝘁𝗼 𝟭𝟮 𝗙𝘂𝗹𝗹𝘆 𝗙𝘂𝗻𝗱𝗲𝗱 𝗣𝗵𝗗 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝗙𝗙𝗲𝗰𝗧🚨 🔬 Join an international network driving innovative treatments and delivery methods for a variety of disorders with leading experts in RNA therapeutics 🌍 🔗 𝗔𝗽𝗽𝗹𝘆 𝗻𝗼𝘄: euraxess.ec.europa.eu/jobs/296420 more info: www.effect-dn.eu

12 PhDs on Antisense oligonucleotide research to foster the full therapeutic potential of antisense technology across tissues

EFFecT (European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across Tissues) is a Marie Skłodowska-Curie Doctoral Network (2025-2028), offering 12 PhD positions.

euraxess.ec.europa.eu

5 Partners & 1 Associated partner of #EFFecT are present at SMOT (Synergistic Meeting on Oligonucleotide Therapeutics) celebrating #rarediseaseday.@radboudumc.bsky.social @dutchantisense.bsky.social @uvsq.bsky.social #ucl @cbm-csic-uam.bsky.social @varechavala.bsky.social

🚨 Only 3 Weeks Left to Apply! 🚨 Passionate about antisense oligonucleotide (ASO) therapeutics? Looking for a PhD opportunity in this cutting-edge field? The EFFecT consortium is recruiting!

Check out our latest work! Preclinical in vitro and safety and in vivo biodistribution of #antisense #oligonucleotides targeting a recurrent genetic variant in ABCA4 present in patients with #Stargardt disease. A big first step towards therapeutic intervention. www.nature.com/articles/s43...

Preclinical assessment of splicing modulation therapy for ABCA4 variant c.768G>T in Stargardt disease - Communications Medicine

Karjosukarso et al. investigate antisense oligonucleotides targeting aberrant splicing caused by a recurrent ABCA4 variant in Stargardt disease. A candidate therapeutic molecule that shows a favorable...

nature.com

Today part of the @dutch-antisense.bsky.social organizing committee visited the venues for the #DATS2025 in Groningen! We cannot wait to welcoming you in June! Registrations will open soon, stay tuned! www.dutchantisense.org @ronaldbuijsen.bsky.social